Subtype
Pancreatobiliary Carcinoma
CI-CAN-00001365Explore in graph →
700 active trials8 approved drugs60 evidence items
- NCIt
- C166418
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001365Explore in graph →
Clinical trials
2,132 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (303)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07476651 | Scout Dose of Resin Microspheres(LASER) | recruiting | N/A | 30 | Seoul National University HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04837118 | Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study | active not recruiting | N/A | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 |
| clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06659705 | Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)(INDIGO-FAPI) | recruiting | Phase 2 | 35 | Institut CurieOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06799637 | Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | recruiting | Phase 1 / Phase 2 | 350 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07036978 | Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer | not yet recruiting | — | 140 | Chang Gung Memorial HospitalOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07126158 | Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma | recruiting | Phase 2 | 36 | Washington University School of MedicineOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05821556 | Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients | recruiting | Phase 2 | 240 | National Cancer Institute, NaplesOTHER | 2 | Apr 14, 2026 | clinicaltrials |
| NCT04406831 | The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer | recruiting | — | 200 | Nuvance HealthOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05257993 | Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 71 | Onconic Therapeutics Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06454383 | Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer | recruiting | Phase 1 | 19 | City of Hope Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07114861 | The KN510713 Study in Combination With mFOLFIRINOX | recruiting | Phase 1 / Phase 2 | 30 | New Cancer Cure-Bio Co.,Ltd.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05624918 | A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma | recruiting | Phase 2 | 38 | Ashish ManneOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07516392 | Study of a Polygenic Risk Score to Predict the Risk of Pancreatic Ductal Adenocarcinoma(PRE-PDAC) | not yet recruiting | N/A | 1,140 | Catholic University of the Sacred HeartOTHER | 0 | Apr 8, 2026 | clinicaltrials |
| NCT04449406 | Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers(UroPanc) | active not recruiting | — | 3,500 | Queen Mary University of LondonOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05743049 | Collection of Circulating Biomarkers in Pancreatic Cancer | recruiting | — | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06639724 | Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer | recruiting | Phase 1 | 36 | University of California, San DiegoOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07514533 | The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma | not yet recruiting | Phase 2 | 60 | Sir Run Run Shaw HospitalOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT04622423 | Advanced Therapies for Liver Metastases(LiMeT) | recruiting | — | 625 | IRCCS San RaffaeleOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06910722 | Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After SIRT and Chemotherapy(RIS-TH) | recruiting | N/A | 36 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | active not recruiting | Phase 2 | 350 | Actuate Therapeutics Inc.INDUSTRY | 7 | Apr 3, 2026 | clinicaltrials |
| NCT06125769 | LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA)(LITALHICA) | recruiting | N/A | 50 | Azienda Sanitaria OspedalieraOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06850623 | Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer(ENACT) | recruiting | Phase 2 | 25 | EXACT Therapeutics ASINDUSTRY | 2 | Apr 3, 2026 | clinicaltrials |
| NCT07107750 | Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer | recruiting | Phase 1 | 48 | Washington University School of MedicineOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06807437 | Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula | recruiting | Phase 3 | 274 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07144917 | Immunoparalysis After Pancreaticoduodenectomy(ImPaHLA) | recruiting | — | 100 | Hospices Civils de LyonOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04281290 | Electrochemotherapy of Posterior Resection Surface for Lowering Disease Recurrence Rate in Pancreatic Cancer (PanECT Study)(PanECT) | active not recruiting | N/A | 10 | University Medical Centre LjubljanaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07324096 | A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer(AI-PACED) | recruiting | N/A | 100 | Mayo ClinicOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07493421 | To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement. | recruiting | N/A | 20 | Unidade Local de Saúde São JoãoOTHER_GOV | 2 | Mar 25, 2026 | clinicaltrials |
| NCT07089940 | OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Early Phase 1 | 12 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07392541 | Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer | recruiting | Phase 1 / Phase 2 | 29 | Tongji HospitalOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05191940 | Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)(LAPC) | recruiting | N/A | 30 | EBG MedAustron GmbHINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06140134 | Liver Transplantation in Intrahepatic Cholangiocarcinoma | recruiting | — | 30 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04862260 | Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma | active not recruiting | Early Phase 1 | 3 | CHU de Quebec-Universite LavalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06648057 | Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab | recruiting | — | 100 | CHA UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480928 | Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma(DUAL-NK-PDAC) | recruiting | Phase 1 / Phase 2 | 42 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03384238 | Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery | recruiting | Phase 1 / Phase 2 | 27 | George PoultsidesOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07477418 | PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)(PRISM-TAMP) | not yet recruiting | Phase 1 / Phase 2 | 10 | University of VermontOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06474091 | Liquid Biopsy MonitORing Of CholangioCarcinOma for Treatment Response and Prognostic Outcomes (MOROCCO) | enrolling by invitation | — | 100 | Mayo ClinicOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06756074 | Reinforced Pancreaticojejunostomy With or Without glubran2 | recruiting | Phase 2 | 100 | Minia UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06712797 | Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center(PANTHER-PIC) | active not recruiting | N/A | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06151223 | A Prospective Registry for Patients at High-Risk for Pancreatic Cancer | recruiting | — | 5,000 | Mayo ClinicOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT00830557 | Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders | recruiting | — | 20,000 | Mayo ClinicOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04792463 | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome | recruiting | — | 500 | Mohamed Abdel-RahmanOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06646055 | AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 110 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06859684 | Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)(HAIC-quad) | recruiting | Phase 2 | 25 | West China HospitalOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06895031 | Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS(STAR) | recruiting | Phase 2 | 210 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07454486 | TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort(TRACE-BTC) | not yet recruiting | — | 300 | Aarhus University HospitalOTHER | 1 | Mar 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 16, 2026source: clinicaltrials